Clinical trials in cancer chemotherapy

Cancer

Volumn 40, Issue 1 S, 1977, Pages 544-557

  Carter, Stephen K ^a,b,c  

^a Stanford University ^*  (United States)

^b STANFORD UNIVERSITY   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CHLORMETHINE; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; FLUOROURACIL; LOMUSTINE; MELPHALAN; METHOTREXATE; PREDNISONE; PROGESTERONE; SEMUSTINE; VINBLASTINE; VINBLASTINE SULFATE; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; DRUG INDICATION; DRUG THERAPY; MAJOR CLINICAL STUDY; THERAPY;

ANIMAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; DRUG EVALUATION; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; FEMALE; HUMAN; HUMAN EXPERIMENTATION; MALE; NEOPLASMS; NEOPLASMS, EXPERIMENTAL; SPECIES SPECIFICITY;

EID: 0017742920     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/1097-0142(197707)40:1+<544::AID-CNCR2820400721>3.0.CO;2-#     Document Type: Article

References (54)

1. Combination chemotherapy as adjuvant treatment in operable breast cancer
2. Combination chemotherapy of carcinoma of the breast
3. Treatment of prostatic cancer by the Veterans Administration Cooperative Urological Group
4. Study design principles for the clinical evaluation of new drugs as developed by the chemotherapy program of the National Cancer Institute
5. Planning combined therapy—the interaction of experimental and clinical studies
6. 5‐(3,3‐dimethyl‐l‐triazeno)‐imidazole‐4‐carboxamide (DTIC, DIC, NSC 45388)—a new antitumor agent with activity against malignant melanoma
7. Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy
8. The chemical therapy of breast cancer
9. Large Bowel Cancer—the current status of treatment
10. Chemotherapy of cancer
11. Integration of chemotherapy into a combined modality treatment of solid tumors. III. Gastric cancer
12. Studies on the folic acid vitamins. VII. The effect of large doses of amithopterin in patients with cancer
13. Amputation and Adrimycin in primary osteosarcoma
14. Clinical trials with 1, 3 Bis‐(2‐chloroethyl)‐1‐nitrosourea, NSC 409962
15. Perspectives on research in gynecologic oncology
16. Chemotherapy in the treatment of leukemia and Wilms' tumor
17. The epidemiology of cancer therapy. II. The clinical course: data, decision and temproal demarcations
18. L‐Pheny‐lalanine mustard (L‐PAM) in the management of primary breast cancer—a report of early findings
19. Combination chemotherapy in advanced Hodgkins's disease: Induction and maintenance of remission
20. Quantitative comparison of tox‐icity of anti‐cancer agents in mouse, rat, hamster, dog, monkey and man
21. The determination of the number of patients required in a preliminary and follow up trial of a new chemotherapeutic agent
22. Non‐randomized controls in cancer clinical trials
23. Experimental design of clinical trials
24. Coordinated Phase I studies for cooperative chemotherapy groups
25. Quantitative prediction of drug toxicity in humans from toxicology in small and large animals
26. Experimental evaluation of potential anticancer agents. XII. Quantitative drug response of Sa 180, Ca 755, and leukemia L1210 systems to a “standard list” of “active” and “inactive” agents
27. Clinical studies with 1‐(2‐chloroethyl)‐3‐cyclohexyl‐1‐nitrosourea (NSC 79037)
28. Quantitative relationships between toxic doses of antitumor chemotherapeutic agents in animals and man
29. Treatment of clinically localized Ewing's sarcoma with radiotherapy and combination chemotherapy
30. Adjuvant methotrexate and citrovorum‐factor treatment of osteoseric sarcoma
31. Integrated therapy for Ewing's sarcoma
32. Clinical examination of drugs, a scientific and ethical challenge
33. Effects of patient selection on results on Phase II chemotherapy trials in gastrointestinal cancer
34. Effects of 4‐fluorouracil (NSC 19893) in 389 patients with cancer
35. Phase II Evaluation of Adriamycin in human neoplasia
36. Predicting anti‐cancer drug effects in man from animal laboratory studies
37. The use of body surface area as a criterion of drug dosage in cancer chemotherapy
38. Embryonal rhabdomyosarcoma
39. Coordinated treatment of childhood rhabdomyosarcoma with surgery, radiotherapy and combination chemotherapy
40. The antitumor spectrum of cyclophosphamide
41. Mouse to man: Statistical problems in bringing a drug to clinical trial
42. How do you know you've done any better
43. Experimental evaluation of potential anticancer agents XIII. On the criteria and kinetics associated with “curability” of experimental leukemia
44. Successful therapy for Wilms' tumor
45. Comparison of survival curves 1956 versus 1962 in children with Wilms' tumor and neuroblastoma
46. Effect of CCNU (NSC 79037) on bronchogenic carcinoma
47. Bleomycin, an antitumor antibiotic. Clinical experience in 274 patients
48. The randomization and stratification of patients to clinical trials
49. Keynote address on biostatistics and data retrieval